Basit öğe kaydını göster

dc.contributor.authorBasturk, Abdulkadir
dc.contributor.authorCagirgan, Seckin
dc.contributor.authorDagdas, Simten
dc.contributor.authorKoca, Ebru
dc.contributor.authorKadikoylu, Gurhan
dc.contributor.authorGÜNDÜZ, EREN
dc.contributor.authorYILMAZ, MEHMET
dc.contributor.authorBekoz, Hulseyin
dc.contributor.authorUral, Ali Ugur
dc.contributor.authorArat, Mutlu
dc.contributor.authorBesisik, Sevgi
dc.contributor.authorTekgunduz, Emre
dc.contributor.authorDEMİRKAN, FATİH
dc.contributor.authorVURAL, FİLİZ
dc.contributor.authorGÖKER, HAKAN
dc.contributor.authorOzdogu, Hakan
dc.contributor.authorKİKİ, İlhami
dc.contributor.authorAltuntas, Fevzi
dc.contributor.authorOzgur, Gokhan
dc.contributor.authorOzkan, Hasan Atilla
dc.contributor.authorNevruz, Oral
dc.contributor.authorBOLAMAN, ALİ ZAHİT
dc.contributor.authorAkyol, Alev
dc.contributor.authorOzturk, Erman
dc.contributor.authorAlbayrak, Murat
dc.contributor.authorAYDOĞDU, İSMET
dc.contributor.authorKAYNAR, LEYLAGÜL
dc.contributor.authorERKURT, MEHMET ALİ
dc.date.accessioned2021-03-03T16:45:03Z
dc.date.available2021-03-03T16:45:03Z
dc.date.issued2017
dc.identifier.citationTekgunduz E., DEMİRKAN F., VURAL F., GÖKER H., Ozdogu H., KİKİ İ., AYDOĞDU İ., KAYNAR L., ERKURT M. A. , Cagirgan S., et al., "Current practice of autologous hematopoietic progenitor cell mobilization in adult patients with multiple myeloma and lymphoma: The results of a survey from Turkish hematology research and education group (ThREG)", TRANSFUSION AND APHERESIS SCIENCE, cilt.56, sa.6, ss.804-808, 2017
dc.identifier.issn1473-0502
dc.identifier.otherav_45f8aced-9a45-48d8-8ad6-2e8adba6a648
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/50667
dc.identifier.urihttps://doi.org/10.1016/j.transci.2017.11.010
dc.description.abstractAutologous hematopoietic cell transplantation (AHCT) is an established treatment option for adult patients presenting with multiple myeloma (MM), Hodgkin lymphoma (HL) and various subtypes of non-Hodgkin lymphoma (NHL) in upfront and/or relapsed/refractory disease settings. Although there are recently published consensus guidelines addressing critical issues regarding autologous hematopoietic progenitor cell mobilization (HPCM), mobilization strategies of transplant centers show high variability in terms of routine practice. In order to understand the current institutional policies regarding HPCM in Turkey and to obtain the required basic data for preparation of a national positional statement on this issue, Turkish Hematology Research and Education Group (ThREG) conducted a web-based HPCM survey. The survey was designed to include multiple-choice questions regarding institutional practice of HPCM in adults presenting MM, HL, and NHL. The representatives of 27 adult HCT centers participated to the study. Here we report the results of this survey shedding light on the real world experience in Turkey in terms of autologous HPCM mobilization strategies in patients presenting with MM and lymphoma. (C) 2017 Elsevier Ltd. All rights reserved.
dc.language.isoeng
dc.subjectDahili Tıp Bilimleri
dc.subjectHematoloji
dc.subjectİç Hastalıkları
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectHEMATOLOJİ
dc.subjectKlinik Tıp
dc.titleCurrent practice of autologous hematopoietic progenitor cell mobilization in adult patients with multiple myeloma and lymphoma: The results of a survey from Turkish hematology research and education group (ThREG)
dc.typeMakale
dc.relation.journalTRANSFUSION AND APHERESIS SCIENCE
dc.contributor.departmentDr. Abdurrahman Yurtaslan Oncology Hospital , ,
dc.identifier.volume56
dc.identifier.issue6
dc.identifier.startpage804
dc.identifier.endpage808
dc.contributor.firstauthorID248209


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster